Search Within

Owen O'connor

Formats
  1. Meeting Abstract (55)
  2. Journal Article (42)
  3. Book Section (1)
Groups
  1. Department of Medicine (57)
  2. Hematologic Malignancies, Division of (48)
  3. Center for Hematologic Malignancies (45)
  4. Lymphoma (42)
  5. Nursing (23)
  6. Population Sciences Research Program (21)

More Groups

People
  1. Andrew Zelenetz (39)
  2. Craig Moskowitz (35)
  3. David Straus (30)
  4. Carol Portlock (28)
  5. Paul Hamlin (23)
  6. Ariela Noy (22)

More People

Years
  1. 2010 (2)
  2. 2009 (2)
  3. 2008 (3)
  4. 2007 (8)
  5. 2006 (19)
  6. 2005 (17)

More Years

Publications
  1. Blood (30)
  2. Journal of Clinical Oncology (18)
  3. British Journal of Haematology (7)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (5)
  5. Clinical Cancer Research (4)
  6. Leukemia and Lymphoma (4)

More Publications

Publishers
  1. American Society of Hematology (30)
  2. American Society of Clinical Oncology (18)
  3. American Association for Cancer Research (11)
  4. John Wiley & Sons (7)
  5. Taylor & Francis Group (5)
  6. Springer (4)

More Publishers

Results (98)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders
    Meeting Abstract

    Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Final results from a phase I trial of ixabepilone in patients with advanced malignancies and lymphoma
    Meeting Abstract

    Aghajanian, C.; O'connor, O.; Cohen, M.; Peck, R.; Burris, H.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Journal Article

    Fisher, R. I.; Bernstein, S. H.; Kahl, B. S.; Djulbegovic, B.; Robertson, M. J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J. P.; Lonial, S.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma
    Journal Article

    Toner, L. E.; Vrhovac, R.; Smith, E. A.; Gardner, J.; Heaney, M.; Gonen, M.; Teruya-Feldstein, J.; Sirotnak, F.; O'Connor, O. A.
    Clinical Cancer Research (2006)

    Fulltext@MSK | Save
  • An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib
    Journal Article

    Stubblefield, M. D.; Slovin, S.; Macgregor-Cortelli, B.; Muzzy, J.; Scher, H.; Wright, J.; Esseltine, D.; Schenkein, D.; O'Connor, O. A.
    Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: Is there CD20 antigen upregulation?
    Journal Article

    Portlock, C. S.; O'Connor, O. A.; Straus, D. J.; Rosenzweig, L.; Dumitrescu, O.; Lin, O.; Maslak, P.
    Leukemia and Lymphoma (2006)

    Fulltext@MSK | Save
  • Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas
    Journal Article

    Paoluzzi, L.; O'Connor, O. A.
    BioDrugs (2006)

    Fulltext@MSK | Save
  • The combination of the proteasome inhibitor bortezomib and the Bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide
    Journal Article

    O'Connor, O. A.; Smith, E. A.; Toner, L. E.; Teruya-Feldstein, J.; Frankel, S.; Rolfe, M.; Wei, X.; Liu, S.; Marcucci, G.; Chan, K. K.; more...
    Clinical Cancer Research (2006)

    Fulltext@MSK | Save
  • Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Journal Article

    O'Connor, O. A.; Heaney, M. L.; Schwartz, L.; Richardson, S.; Willim, R.; Macgregor-Cortelli, B.; Curly, T.; Moskowitz, C.; Portlock, C.; Horwitz, S.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • New drugs for the treatment of advanced-stage diffuse large cell lymphomas
    Journal Article

    O'Connor, O. A.; Hamlin, P.
    Seminars in Hematology (2006)

    Fulltext@MSK | Save